<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="case-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Bras Pneumol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Bras Pneumol</journal-id>
      <journal-title-group>
        <journal-title>Jornal Brasileiro de Pneumologia : Publica&#xE7;a&#x30B;o Oficial da Sociedade Brasileira de Pneumologia e Tisilogia</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1806-3713</issn>
      <issn pub-type="epub">1806-3756</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Pneumologia e Tisiologia</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">24831405</article-id>
      <article-id pub-id-type="pmc">4083635</article-id>
      <article-id pub-id-type="publisher-id">S1806-37132014000200188</article-id>
      <article-id pub-id-type="doi">10.1590/S1806-37132014000200014</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Case Report</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Lymphadenitis caused by infection with an isoniazid- and
rifampin-resistant strain of <italic>Mycobacterium bovis </italic>BCG in an infant
with IFN-&#x3B3;/IL-12 pathway defect<xref ref-type="fn" rid="fn01">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Diniz</surname>
            <given-names>Lilian Martins Oliveira</given-names>
          </name>
          <role>Adjunct Professor</role>
          <aff>Federal University of Minas Gerais School of Medicine, Belo Horizonte,
<country>Brazil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#xE3;es</surname>
            <given-names>Tiago</given-names>
          </name>
          <role>Physician</role>
          <aff>Federal University of Minas Gerais School of Medicine Hospital das Cl&#xED;nicas,
Belo Horizonte, <country>Brazil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Oliveira</surname>
            <given-names>Maria das Gra&#xE7;as Rodrigues</given-names>
          </name>
          <role>Pediatrician</role>
          <aff>Federal University of Minas Gerais School of Medicine Hospital das Cl&#xED;nicas,
Belo Horizonte, <country>Brazil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Jorge Andrade</given-names>
          </name>
          <role>Full Professor</role>
          <aff>Federal University of Minas Gerais School of Medicine, Belo Horizonte,
<country>Brazil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>de Miranda</surname>
            <given-names>Silvana Spindola</given-names>
          </name>
          <role>Adjunct Professor</role>
          <aff>Federal University of Minas Gerais School of Medicine, Belo Horizonte,
<country>Brazil</country></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c01"><bold>Correspondence to: </bold>Silvana Sp&#xED;ndola de Miranda Departamento de Cl&#xED;nica
M&#xE9;dica, Faculdade de Medicina-UFMG Avenida Alfredo Balena, 190, 2 andar, Santa
Efig&#xEA;nia CEP 30130-100, Belo Horizonte, MG, Brasil Tel. 55 31 3248-9599 E-mail:
<email>spindola@medicina.ufmg.br</email></corresp>
      </author-notes>
      <pub-date pub-type="epub-ppub">
        <season>Mar-Apr</season>
        <year>2014</year>
      </pub-date>
      <!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' -->
      <pub-date pub-type="ppub">
        <season>Mar-Apr</season>
        <year>2014</year>
      </pub-date>
      <volume>40</volume>
      <issue>2</issue>
      <fpage>188</fpage>
      <lpage>192</lpage>
      <history>
        <date date-type="received">
          <day>25</day>
          <month>4</month>
          <year>2013</year>
        </date>
        <date date-type="accepted">
          <day>27</day>
          <month>5</month>
          <year>2013</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an Open Access article distributed under the terms of the Creative
Commons Attribution Non-Commercial License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the
original work is properly cited.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>We report a rare case in a female infant (age, 3.5 months) with primary
immunodeficiency (IFN-&#x3B3;/IL-12 pathway defect) who presented with suppurative
lymphadenitis after <italic>Mycobacterium bovis </italic>BCG vaccination. The strain
of <italic>M. bovis</italic> BCG identified was found to be resistant to isoniazid
and rifampin. The patient was treated with a special pharmacological regimen
involving isoniazid (in a limited, strategic manner), ethambutol, streptomycin, and
IFN-&#x3B3;, after which there was complete resolution of the lesions.</p>
      </abstract>
      <kwd-group>
        <kwd>BCG vaccine</kwd>
        <kwd>Interferon-gamma</kwd>
        <kwd>Tuberculosis, multidrug-resistant</kwd>
      </kwd-group>
      <counts>
        <fig-count count="2"/>
        <ref-count count="15"/>
        <page-count count="5"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro">
      <title>Introduction</title>
      <p>BCG is an attenuated strain of <italic>Mycobacterium bovis</italic> that is present in
the tuberculosis vaccine, which was first used in humans in 1922.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> The vaccine produces an artificial primary infection with non-virulent
bacilli in order to increase resistance to a future infection with virulent
bacilli.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup>
</p>
      <p>The World Health Organization recommends vaccination with the BCG vaccine for all
newborns in areas with a high prevalence of tuberculosis as a means to prevent the
disease.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> In Brazil, the use of the BCG vaccine for many years has demonstrated the
effectiveness of vaccination, with minimal adverse reactions, and with severe
complications occurring only rarely.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup>
</p>
      <p>During the natural course of the vaccination lesion, nonsuppurative axillary,
supra-axillary, or infraclavicular lymph node swelling can be seen. However, severer
lesions caused by <italic>M. bovis</italic> BCG strains can be found in patients with
immunodeficiency, who should be treated with a combination regimen of drugs, such as
isoniazid, rifampin, ethambutol, and ciprofloxacin.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>-</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup>
</p>
      <p>The treatment of disease caused by BCG can be complicated by resistance to pyrazinamide,
which is inherent to all strains of <italic>M. bovis</italic>, as well as by
intermediate resistance of some strains to isoniazid and by the emergence of acquired
resistance during inappropriate therapy.<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>
</p>
      <p>The authors report a case of an infant with primary immunodeficiency who had suppurative
lymphadenitis after <italic>M. bovis</italic> BCG vaccination. The strain of <italic>M.
bovis</italic> BCG identified was found to be resistant to isoniazid and
rifampin.</p>
    </sec>
    <sec>
      <title>Case report</title>
      <p>A female infant (age, 3.5 months) was brought by her mother to the Department of
Pediatric Infectious Diseases of the Federal University of Minas Gerais <italic>Hospital
das Cl&#xED;nicas</italic> because of "inflammation" at the BCG vaccination site. It was
reported that there was a family history of two cousins who had experienced the same
adverse event after BCG vaccination and had died with suspected primary immunodeficiency
in the first year of life. The physician who treated the infant noted the presence of a
granulomatous lesion (not suggestive of secondary infection) at the vaccination site, as
well as ipsilateral suppurative lymphadenitis (<xref ref-type="fig" rid="f01">Figure
1</xref>), and the patient was started on isoniazid therapy (10 mg/kg daily for 45
days). The lymphadenitis resolved during treatment. However, after discontinuation of
the drug, the lesion reappeared. The patient was prescribed isoniazid for two additional
months. The lesion resolved, but, at the end of drug treatment, it returned.</p>
      <p>
<fig id="f01" orientation="portrait" position="float"><label>Figure 1</label><caption><title>Suppurative right axillary and infra-axillary lesions after BCG
vaccination.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-02-00188-gf01"/></fig>
</p>
      <p>The infant was referred to the Immunodeficiency Outpatient Clinic of the Federal
University of Minas Gerais <italic>Hospital das Cl&#xED;nicas</italic> with suspected primary
immunodeficiency. Initial immunological assessment showed that serum immunoglobulin
levels and lymphocyte subpopulation levels were within the normal range. Because the
initial immunological profile was normal and the clinical course was relatively benign,
we hypothesized that the patient had an IFN-&#x3B3;/IL-12 pathway defect. Serology for HIV was
negative.</p>
      <p>At that same time, we chose to biopsy the affected lymph node. Smear microscopy and
mycobacterial culture of these clinical specimens were requested. Because of the
isoniazid-induced reactivation of the lesion and the family history of primary
immunodeficiency, the patient was started on a combination regimen of isoniazid (10
mg/kg daily), rifampin (10 mg/kg daily), and ethambutol (25 mg/kg daily). Ethambutol was
introduced after a literature review, which showed that this drug is introduced in
severer forms of infection with <italic>M. bovis</italic> BCG.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>-</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup> The infant was also referred to the department of ophthalmology for
evaluation because of the risk of ethambutol-induced optic neuritis. In the second month
of treatment, there was optic disc blurring bilaterally. At that same time, the results
of smear microscopy and culture of the lymph node biopsy specimen were positive for the
<italic>M. tuberculosis</italic> complex, and susceptibility testing showed
resistance to isoniazid. In view of the partial resolution of lymphadenitis and the
possibility of drug-induced optic neuritis, ethambutol was discontinued, and rifampin
and isoniazid were continued despite resistance to isoniazid.</p>
      <p>In the eighth month of treatment, the infant was hospitalized with secondary infection
at the biopsy site. A chest CT performed during hospitalization showed diffuse
coalescent axillary lymphadenopathy on the right, with necrotic and fistulized lymph
nodes, which indicated lesion activity. A second lymph node biopsy was performed, and
the specimen was sent to the Professor H&#xE9;lio Fraga Referral Center, located in the city
of Rio de Janeiro, Brazil, for mycobacterial and molecular analysis of the strain. The
laboratory test results showed that it was the <italic>M. bovis</italic> BCG strain. The
identification tests used were basic biochemical tests and polymerase chain reaction
restriction analysis of the <italic>hsp65</italic> gene. Susceptibility testing was
performed in BACTEC Mycobacteria Growth Indicator Tube (MGIT) 960 (Becton Dickinson,
Sparks, MD, USA), the result of which showed resistance to isoniazid and also to
rifampin. Sequencing of the <italic>rpo</italic>B gene detected the D516V mutation, and
sequencing of the <italic>kat</italic>G gene detected the S315T mutation.</p>
      <p>Given the results, we chose to continue treatment with isoniazid, restart ethambutol,
and have the patient have ophthalmic follow-up weekly, as well as to add 30 doses of
streptomycin (25 mg/kg daily) on alternate days for six months and discontinue rifampin.
The ophthalmic lesion remained stable throughout the treatment period. Given the
difficulty of the case, streptomycin was used because it is bactericidal and it is a
first-line drug, as well as because there is a lack of knowledge about the true
<italic>in vivo</italic> response to isoniazid.</p>
      <p>The hypothesis of IFN-&#x3B3;/IL-12 pathway defect was confirmed by molecular tests that
detected a homozygous mutation in IL-12 receptor &#x3B2;<sub>1</sub>, thus excluding probable
severe combined immunodeficiency (SCID). Therefore, subcutaneous IFN-&#x3B3; three times
weekly was added to the treatment regimen.</p>
      <p>After six months of treatment, the axillary lesion had completely resolved (<xref ref-type="fig" rid="f02">Figure 2</xref>). At this writing, three years after the
onset of the condition, the patient remained free of lymphadenitis, and the ocular
lesion remained stable, with no impact on vision.</p>
      <p>
<fig id="f02" orientation="portrait" position="float"><label>Figure 2</label><caption><title>Healed lesions in the right axillary and infra-axillary regions after
treatment.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-02-00188-gf02"/></fig>
</p>
    </sec>
    <sec sec-type="discussion">
      <title>Discussion</title>
      <p>Adverse reactions to the BCG vaccine vary according to the type of strain, bacterial
load, administration of the vaccine, and host characteristics. Nonsuppurative reactive
lymphadenitis can occur in children in the first months after administration of the
vaccine and is mostly due to incorrect technique of administration. In Brazil, isoniazid
has been used in the treatment of suppurative lymphadenopathy secondary to the vaccine
in immunocompetent patients. This recommendation is based on the fact that the Brazilian
strain of BCG is usually sensitive to this drug in in vitro tests.<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> However, in the present case, the BCG strain proved to be resistant to
isoniazid and rifampin, showing probable <italic>in vivo</italic> response to the
combination of these drugs with other drugs.</p>
      <p>Nevertheless, the vaccine can cause complications that are more severe and, in most
cases, occur in patients with immunosuppression. The incidence of disseminated
<italic>M. bovis</italic> BCG disease in European countries is estimated to be two
cases per million children vaccinated, and the disease occurs only occasionally in
immunocompetent children.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup> In their study, Talbot et al. reported a rate of immune defects of 86% in
children diagnosed with disseminated disease.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> In the literature, there have been reports of complications in HIV-infected
patients and in patients with primary immunodeficiency.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> Hesseling et al. described a series of 25 patients diagnosed with severe
<italic>M. bovis</italic> BCG infection associated with primary
immunodeficiency.<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Santos et al. described the cases of three patients with vaccine-induced
infection, one of whom had IFN-&#x3B3;/IL-12 pathway deficiency.<sup>(</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup> An IFN-&#x3B3;/IL-12 pathway defect is an immunodeficiency disorder in which
there is increased susceptibility to infections with microorganisms of the genera
<italic>Mycobacterium</italic> and <italic>Salmonella</italic>.<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup> It is classified as a congenital defect of phagocyte number, function, or
both. Host defenses against these bacteria strongly depend on the functional integrity
of mononuclear phagocytes and their interaction with T lymphocytes. T lymphocytes and
natural killer cells of affected patients express a defective IL-12 receptor on their
cell surfaces, leading to low production of IFN-&#x3B3;, which is the major factor responsible
for mycobacterial death.<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup> The diagnosis of IFN-&#x3B3;/IL-12 pathway defects requires a tiered approach and
laboratory support.<sup>(</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup> In patients with severe disseminated mycobacterial infection, other
immunodeficiency disorders, such as severe combined immunodeficiency, should be excluded
first. In some cases, the treatment of IFN-&#x3B3;/IL-12 pathway defects requires aggressive
use of drugs against the mycobacterium and subcutaneous IFN-&#x3B3; replacement therapy as a
treatment option.<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> In the present case report, ancillary tests confirmed this deficiency,
which favored the development of lesions due to <italic>M. bovis</italic> BCG.</p>
      <p>A system for classification of <italic>M. bovis</italic> BCG disease in
immunocompromised patients was developed by Talbot et al. and subsequently revised by
Hesseling et al.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Infection is classified on the basis of its presentation as local,
regional, distant, or disseminated disease. Regional disease is defined as that in which
there is a lesion at the vaccination site and ipsilateral regional lymph node
involvement, with lymphadenopathy and fistula formation and/or suppuration, as in the
case described here.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup>
</p>
      <p>We report the course of <italic>M. bovis</italic> BCG infection in an infant with
primary immunodeficiency who presented with a regional lesion located ipsilateral to the
vaccination site. The lesion was unresponsive to the recommended treatment with
isoniazid, and the strain identified was found to be resistant to two drugs (rifampin
and isoniazid). Although susceptibility testing showed resistance to isoniazid, we chose
to continue treatment with this drug, since testing using a critical concentration does
not quantify the level of resistance (low, moderate, or high), which is determined using
a minimum inhibitory concentration (MIC).<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup> The level of <italic>in vitro</italic> resistance to isoniazid was not
quantified, since an MIC was not performed, as well as not reflecting the <italic>in
vivo</italic> reality, and the mutation found (the <italic>kat</italic>G S315T
mutation) may be related to moderate resistance to isoniazid. Since ethambutol was
withdrawn from the regimen because of suspected optic neuritis, there may have been
strain selection, with acquisition of resistance to rifampin. Rifampin was discontinued,
given that the mutation found in the <italic>rpo</italic>B region (the D516V mutation)
is in most cases related to a high level of resistance.<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup> There have been studies of mutations and MIC associated with clinical
response for <italic>M. tuberculosis</italic>, but there have been no reports regarding
<italic>M. bovis</italic> BCG.</p>
      <p>Ethambutol-induced optic neuritis was ruled out, since the alteration in the optic disk
remained stable throughout the follow-up period. The favorable outcome was possible,
despite resistance to isoniazid, because of the combination of streptomycin and
ethambutol, as well as because of the inclusion of the immunomodulator, resulting in
resolution of the lesions.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn id="fn01" fn-type="other">
        <label>*</label>
        <p>Study carried out at the Federal University of Minas Gerais, Belo Horizonte,
Brazil.</p>
      </fn>
      <fn fn-type="supported-by">
        <p><bold>Financial support:</bold> : This study received financial support from the <italic>Funda&#xE7;&#xE3;o de Amparo &#xE0;
Pesquisa do Estado de Minas Gerais</italic> (FAPEMIG, Foundation for the Support
of Research in the state of Minas Gerais).</p>
      </fn>
    </fn-group>
    <ref-list>
      <title>References</title>
      <ref id="B01">
        <label>1</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <collab>Minist&#xE9;rio da Sa&#xFA;de, Secretaria de Vigil&#xE2;ncia em Sa&#xFA;de. Departamento de
Vigil&#xE2;ncia Epidemiol&#xF3;gica</collab>
          </person-group>
          <source xml:lang="pt">Manual de vigil&#xE2;ncia epidemiol&#xF3;gica dos eventos adversos
p&#xF3;s-vacina&#xE7;&#xE3;o. 2nd Ed.,</source>
          <publisher-loc>Bras&#xED;lia</publisher-loc>
          <publisher-name>Minist&#xE9;rio da Sa&#xFA;de</publisher-name>
          <year>1998</year>
        </element-citation>
      </ref>
      <ref id="B02">
        <label>2</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <collab>World Health Organization</collab>
          </person-group>
          <article-title>BCG vaccine: WHO position paper</article-title>
          <source>Wkly Epidemiol Rec</source>
          <year>2004</year>
          <volume>79</volume>
          <issue>4</issue>
          <fpage>27</fpage>
          <lpage>38</lpage>
          <pub-id pub-id-type="pmid">14768305</pub-id>
        </element-citation>
      </ref>
      <ref id="B03">
        <label>3</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Santos</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Dias</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cordeiro</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cordinh&#xE3;</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lemos</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Rocha</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Severe axillary lymphadenitis after BCG vaccination:
alert for primary immunodeficiencies</article-title>
          <source>J Microbiol Immunol Infect</source>
          <year>2010</year>
          <volume>43</volume>
          <issue>6</issue>
          <fpage>530</fpage>
          <lpage>537</lpage>
          <pub-id pub-id-type="doi">10.1016/S1684-1182(10)60082-5</pub-id>
          <pub-id pub-id-type="pmid">21195982</pub-id>
        </element-citation>
      </ref>
      <ref id="B04">
        <label>4</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Blanche</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Emile</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Jouanguy</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lamhamedi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Altare</surname>
              <given-names>F</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Idiopathic disseminated bacillus Calmette-Gu&#xE9;rin
infection: a French national retrospective study</article-title>
          <source>Pediatrics</source>
          <year>1996</year>
          <volume>98</volume>
          <issue>4</issue>
          <issue-part>Pt 1</issue-part>
          <fpage>774</fpage>
          <lpage>778</lpage>
          <pub-id pub-id-type="pmid">8885960</pub-id>
        </element-citation>
      </ref>
      <ref id="B05">
        <label>5</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hesseling</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Schaaf</surname>
              <given-names>HS</given-names>
            </name>
            <name>
              <surname>Victor</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Beyers</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Marais</surname>
              <given-names>BJ</given-names>
            </name>
            <name>
              <surname>Cotton</surname>
              <given-names>MF</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Resistant Mycobacterium bovis bacillus Calmette-Gu&#xE9;rin
disease: implications for management of bacillus Calmette-Gu&#xE9;rin Disease in human
immunodeficiency virus-infected children</article-title>
          <source>Pediatr Infect Dis J</source>
          <year>2004</year>
          <volume>23</volume>
          <issue>5</issue>
          <fpage>476</fpage>
          <lpage>479</lpage>
          <pub-id pub-id-type="doi">10.1097/01.inf.0000126593.21006.ac</pub-id>
          <pub-id pub-id-type="pmid">15131480</pub-id>
        </element-citation>
      </ref>
      <ref id="B06">
        <label>6</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sicevic</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Generalized BCG tuberculosis with fatal course in two
sisters</article-title>
          <source>Acta Paediatr Scand</source>
          <year>1972</year>
          <volume>61</volume>
          <issue>2</issue>
          <fpage>178</fpage>
          <lpage>184</lpage>
          <pub-id pub-id-type="doi">10.1111/j.1651-2227.1972.tb15922.x</pub-id>
          <pub-id pub-id-type="pmid">4536790</pub-id>
        </element-citation>
      </ref>
      <ref id="B07">
        <label>7</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Fine</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Carneiro</surname>
              <given-names>IA</given-names>
            </name>
            <name>
              <surname>Milstien</surname>
              <given-names>JB</given-names>
            </name>
            <name>
              <surname>Clements</surname>
              <given-names>CJ</given-names>
            </name>
          </person-group>
          <source>Issues relating to the use of BCG immunization programmes.A
discussion document</source>
          <publisher-loc>Geneva</publisher-loc>
          <publisher-name>World Health Organization</publisher-name>
          <year>1999</year>
        </element-citation>
      </ref>
      <ref id="B08">
        <label>8</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sadeghi-Shanbestari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ansarin</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Maljaei</surname>
              <given-names>SH</given-names>
            </name>
            <name>
              <surname>Rafeey</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pezeshki</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Kousha</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Immunologic aspects of patients with disseminated
bacilli Calmette-Guerin disease in north-west of Iran</article-title>
          <source>Ital J Pediatr</source>
          <year>2009</year>
          <volume>35</volume>
          <fpage>42</fpage>
          <lpage>42</lpage>
          <pub-id pub-id-type="doi">10.1186/1824-7288-35-42</pub-id>
          <pub-id pub-id-type="pmid">20030825</pub-id>
        </element-citation>
      </ref>
      <ref id="B09">
        <label>9</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Talbot</surname>
              <given-names>EA</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Silva</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Forthingham</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Disseminated bacille Calmette-Gu&#xE9;rin disease after
vaccination: case report and review</article-title>
          <source>Clin Infect Dis</source>
          <year>1997</year>
          <volume>24</volume>
          <issue>6</issue>
          <fpage>1139</fpage>
          <lpage>1146</lpage>
          <pub-id pub-id-type="doi">10.1086/513642</pub-id>
          <pub-id pub-id-type="pmid">9195072</pub-id>
        </element-citation>
      </ref>
      <ref id="B10">
        <label>10</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hesseling</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Rabie</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Marais</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Manders</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lips</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schaaf</surname>
              <given-names>HS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Bacille Calmette-Gu&#xE9;rin vaccine-induced disease in
HIV-infected and HIV-uninfected children</article-title>
          <source>Clin Infect Dis</source>
          <year>2006</year>
          <volume>42</volume>
          <issue>4</issue>
          <fpage>548</fpage>
          <lpage>558</lpage>
          <pub-id pub-id-type="doi">10.1086/499953</pub-id>
          <pub-id pub-id-type="pmid">16421800</pub-id>
        </element-citation>
      </ref>
      <ref id="B11">
        <label>11</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Costa-Carvalho</surname>
              <given-names>BT</given-names>
            </name>
            <name>
              <surname>Lazzetti</surname>
              <given-names>AV</given-names>
            </name>
            <name>
              <surname>Ferrarini</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Campos</surname>
              <given-names>SO</given-names>
            </name>
            <name>
              <surname>Lazzetti</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Carlasse</surname>
              <given-names>FA</given-names>
            </name>
          </person-group>
          <article-title xml:lang="pt">Salmonella septicemia associated with interleukin 12
receptor b1 (IL-12 Rb1) deficiency [Article in Portuguese]</article-title>
          <source>J Pediatr (Rio J)</source>
          <year>2003</year>
          <volume>79</volume>
          <issue>3</issue>
          <fpage>273</fpage>
          <lpage>276</lpage>
          <pub-id pub-id-type="doi">10.2223/JPED.1031</pub-id>
          <pub-id pub-id-type="pmid">14506539</pub-id>
        </element-citation>
      </ref>
      <ref id="B12">
        <label>12</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Al-Herz</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Bousfiha</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Casanova</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Chapel</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Conley</surname>
              <given-names>ME</given-names>
            </name>
            <name>
              <surname>Cunningham-Rundles</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Primary immunodeficiency diseases: an update on the
classification from the international union of immunological societies expert
committee for primary immunodeficiency</article-title>
          <source>Front Immunol</source>
          <year>2011</year>
          <volume>2</volume>
          <fpage>54</fpage>
          <lpage>54</lpage>
          <!--<pub-id pub-id-type="pmcid">PMC3342372</pub-id>-->
          <pub-id pub-id-type="pmid">22566844</pub-id>
        </element-citation>
      </ref>
      <ref id="B13">
        <label>13</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>de Beaucoudrey</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Samarina</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bustamante</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cobat</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Boisson-Dupuis</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Feinberg</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Revisiting human IL-12R&#xDF;1 deficiency: a survey of 141
patients from 30 countries</article-title>
          <source>Medicine (Baltimore)</source>
          <year>2010</year>
          <volume>89</volume>
          <issue>6</issue>
          <fpage>381</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="doi">10.1097/MD.0b013e3181fdd832</pub-id>
          <pub-id pub-id-type="pmid">21057261</pub-id>
        </element-citation>
      </ref>
      <ref id="B14">
        <label>14</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Rosenzweig</surname>
              <given-names>SD</given-names>
            </name>
            <name>
              <surname>Holland</surname>
              <given-names>SM</given-names>
            </name>
          </person-group>
          <article-title>Defects in the interferon-gamma and interleukin-12
pathways</article-title>
          <source>Immunol Rev</source>
          <year>2005</year>
          <volume>203</volume>
          <fpage>38</fpage>
          <lpage>47</lpage>
          <pub-id pub-id-type="doi">10.1111/j.0105-2896.2005.00227.x</pub-id>
          <pub-id pub-id-type="pmid">15661020</pub-id>
        </element-citation>
      </ref>
      <ref id="B15">
        <label>15</label>
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>B&#xF6;ttger</surname>
              <given-names>EC</given-names>
            </name>
          </person-group>
          <article-title>Drug resistance in Mycobacterium tuberculosis: molecular
mechanisms and laboratory susceptibility testing</article-title>
          <person-group person-group-type="editor">
            <name>
              <surname>Donald</surname>
              <given-names>PR</given-names>
            </name>
            <name>
              <surname>van Helden</surname>
              <given-names>PD</given-names>
            </name>
          </person-group>
          <source>Antituberculosis chemotherapy</source>
          <publisher-loc>Basel</publisher-loc>
          <publisher-name>Karger Medical and Scientific</publisher-name>
          <year>2011</year>
          <fpage>128</fpage>
          <lpage>144</lpage>
          <pub-id pub-id-type="doi">10.1159/000324630</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article id="S01" article-type="translation" xml:lang="pt">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Relato De Caso</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Linfadenite por <italic>Mycobacterium bovis </italic>BCG resistente a
isoniazida e rifampicina em lactente com defeito no eixo IFN-&#x3B3;/IL-12<xref ref-type="fn" rid="fn02">*</xref>
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Diniz</surname>
            <given-names>Lilian Martins Oliveira</given-names>
          </name>
          <role>Professora Adjunta</role>
          <aff>Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG)
<country>Brasil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Guimar&#xE3;es</surname>
            <given-names>Tiago</given-names>
          </name>
          <role>M&#xE9;dico</role>
          <aff>Hospital das Cl&#xED;nicas, Faculdade de Medicina, Universidade Federal de Minas
Gerais, Belo Horizonte (MG) <country>Brasil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Oliveira</surname>
            <given-names>Maria das Gra&#xE7;as Rodrigues de</given-names>
          </name>
          <role>Pediatra</role>
          <aff>Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG)
<country>Brasil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pinto</surname>
            <given-names>Jorge Andrade</given-names>
          </name>
          <role>Professor Titular</role>
          <aff>Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG)
<country>Brasil</country></aff>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Miranda</surname>
            <given-names>Silvana Spindola de</given-names>
          </name>
          <role>Professora Adjunta</role>
          <aff>Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte (MG)
<country>Brasil</country></aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <corresp id="c02"><bold>Endere&#xE7;o para correspond&#xEA;ncia: </bold>Silvana Sp&#xED;ndola de Miranda Departamento
de Cl&#xED;nica M&#xE9;dica, Faculdade de Medicina-UFMG Avenida Alfredo Balena, 190, 2 andar,
Santa Efig&#xEA;nia CEP 30130-100, Belo Horizonte, MG, Brasil Tel. 55 31 3248-9599 E-mail:
<email>spindola@medicina.ufmg.br</email></corresp>
      </author-notes>
      <abstract>
        <p>Relatamos um caso raro em uma lactente com tr&#xEA;s meses e meio de idade, portadora de
imunodefici&#xEA;ncia prim&#xE1;ria (defeito no eixo IFN-&#x3B3;/IL-12), que apresentou linfadenite
supurativa ap&#xF3;s a vacina&#xE7;&#xE3;o por <italic>Mycobacterium bovis </italic>BCG, cepa essa
resistente a isoniazida e rifampicina. Ap&#xF3;s o tratamento com um esquema medicamentoso
especial com isoniazida (de forma estrat&#xE9;gica e limitada), etambutol, estreptomicina
e IFN-&#x3B3;, houve a cura completa das les&#xF5;es.</p>
      </abstract>
      <kwd-group>
        <kwd>Vacina BCG</kwd>
        <kwd>Interferon gama</kwd>
        <kwd>Tuberculose resistente a m&#xFA;ltiplos medicamentos</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <sec>
        <title>Introdu&#xE7;&#xE3;o</title>
        <p>O BCG &#xE9; uma cepa do <italic>Mycobacterium bovis </italic>atenuada presente na vacina
contra a tuberculose, que foi inoculada em humanos pela primeira vez em
1922.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup> A vacina provoca uma primoinfec&#xE7;&#xE3;o artificial, ocasionada por bacilos
n&#xE3;o virulentos, visando aumentar a resist&#xEA;ncia do indiv&#xED;duo em face de uma infec&#xE7;&#xE3;o
ulterior, causada por bacilos virulentos.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup>
</p>
        <p>A Organiza&#xE7;&#xE3;o Mundial da Sa&#xFA;de recomenda a vacina&#xE7;&#xE3;o com a vacina BCG em todos os
neonatos de &#xE1;reas com alta preval&#xEA;ncia de tuberculose como forma de preven&#xE7;&#xE3;o da
doen&#xE7;a.<sup>(</sup>
<xref rid="B02" ref-type="bibr">
<sup>2</sup>
</xref>
<sup>)</sup> No Brasil, seu uso durante muitos anos demonstrou a efici&#xEA;ncia da
vacina&#xE7;&#xE3;o, com o m&#xED;nimo de rea&#xE7;&#xF5;es indesej&#xE1;veis, s&#xF3; raramente induzindo o surgimento
de complica&#xE7;&#xF5;es graves.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>)</sup>
</p>
        <p>Durante a evolu&#xE7;&#xE3;o normal da les&#xE3;o vacinal, o enfartamento ganglionar axilar,
supraclavicular ou infraclavicular n&#xE3;o supurado pode ser observado. No entanto,
les&#xF5;es mais severas causadas pelo <italic>M. bovis</italic> vacinal podem ser
encontradas em pacientes com imunodefici&#xEA;ncia, que devem ser tratados com um esquema
de associa&#xE7;&#xE3;o de f&#xE1;rmacos, tais como isoniazida, rifampicina, etambutol e
ciprofloxacina.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>-</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup>
</p>
        <p>O tratamento da doen&#xE7;a causada pelo BCG pode ser complicado pela resist&#xEA;ncia &#xE0;
pirazinamida, que &#xE9; inerente a todas as cepas de <italic>M. bovis</italic>, assim
como pela resist&#xEA;ncia intermedi&#xE1;ria &#xE0; isoniazida de algumas cepas e pela emerg&#xEA;ncia
de resist&#xEA;ncia adquirida durante terapias inapropriadas.<sup>(</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>,</sup>
<xref rid="B06" ref-type="bibr">
<sup>6</sup>
</xref>
<sup>)</sup>
</p>
        <p>Os autores relatam um caso de uma lactente portadora de imunodefici&#xEA;ncia prim&#xE1;ria com
linfadenite supurativa ap&#xF3;s vacina&#xE7;&#xE3;o pelo BCG, sendo essa cepa resistente a
isoniazida e rifampicina.</p>
      </sec>
      <sec>
        <title>Relato de caso</title>
        <p>Uma lactente de tr&#xEA;s meses e meio de idade veio trazida pela m&#xE3;e ao Servi&#xE7;o de
Infectologia Pedi&#xE1;trica do Hospital das Cl&#xED;nicas da Universidade Federal de Minas
Gerais devido a uma "inflama&#xE7;&#xE3;o" no local da vacina&#xE7;&#xE3;o com BCG. Houve o relato de
hist&#xF3;ria familiar de dois primos que haviam apresentado o mesmo evento adverso ap&#xF3;s a
vacina&#xE7;&#xE3;o com BCG e que vieram a falecer no primeiro ano de vida com suspeita de
imunodefici&#xEA;ncia prim&#xE1;ria. O m&#xE9;dico que atendeu a lactente observou a presen&#xE7;a de uma
les&#xE3;o granulomatosa (n&#xE3;o sugestiva de infec&#xE7;&#xE3;o secund&#xE1;ria) no local da vacina, al&#xE9;m
de linfadenite supurada ipsilateral (<xref ref-type="fig" rid="f03">Figura 1</xref>),
sendo iniciada ent&#xE3;o a terapia com isoniazida (10 mg/kg ao dia) por 45 dias. Houve
resolu&#xE7;&#xE3;o da linfadenite durante o tratamento; por&#xE9;m, ap&#xF3;s a suspens&#xE3;o da medica&#xE7;&#xE3;o,
a les&#xE3;o reapareceu. A isoniazida foi prescrita novamente por mais dois meses. A les&#xE3;o
regrediu mas retornou mais uma vez ao fim do uso da medica&#xE7;&#xE3;o.</p>
        <p>
<fig id="f03" orientation="portrait" position="float"><label>Figura 1</label><caption><title>Les&#xE3;o supurativa axilar e infra-axilar direita ap&#xF3;s a vacina&#xE7;&#xE3;o com
BCG.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-02-00188-gf01-pt"/></fig>
</p>
        <p>A lactente foi encaminhada ao Ambulat&#xF3;rio de Imunodefici&#xEA;ncia do Hospital das
Cl&#xED;nicas da Universidade Federal de Minas Gerais com suspeita de imunodefici&#xEA;ncia
prim&#xE1;ria. Foi submetida &#xE0; avalia&#xE7;&#xE3;o imunol&#xF3;gica inicial, demonstrando valores dentro
da normalidade para a dosagem s&#xE9;rica de imunoglobulinas e de subpopula&#xE7;&#xE3;o de
linf&#xF3;citos. Em fun&#xE7;&#xE3;o da normalidade do perfil imunol&#xF3;gico inicial e do quadro
cl&#xED;nico de evolu&#xE7;&#xE3;o relativamente benigna, foi aventada a hip&#xF3;tese de defeito no eixo
IFN-&#x3B3;/IL-12. A sorologia para o HIV foi negativa.</p>
        <p>Na mesma &#xE9;poca, optou-se pela realiza&#xE7;&#xE3;o de bi&#xF3;psia do linfonodo acometido. Foram
solicitadas baciloscopia e cultura para micobact&#xE9;rias dessas amostras cl&#xED;nicas.
Devido a reativa&#xE7;&#xE3;o da les&#xE3;o com o uso de isoniazida e a hist&#xF3;ria familiar de
imunodefici&#xEA;ncia prim&#xE1;ria, foi iniciado um esquema de associa&#xE7;&#xE3;o dos medicamentos
isoniazida (10 mg/kg ao dia), rifampicina (10 mg/kg ao dia) e etambutol (25 mg/kg ao
dia). O etambutol foi introduzido ap&#xF3;s uma revis&#xE3;o da literatura, a qual indicou que
esse f&#xE1;rmaco &#xE9; introduzido em formas mais graves da infec&#xE7;&#xE3;o por <italic>M.
bovis</italic> BCG.<sup>(</sup>
<xref rid="B01" ref-type="bibr">
<sup>1</sup>
</xref>
<sup>,</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>-</sup>
<xref rid="B05" ref-type="bibr">
<sup>5</sup>
</xref>
<sup>)</sup> A lactente foi tamb&#xE9;m encaminhada ao servi&#xE7;o de oftalmologia para
avalia&#xE7;&#xE3;o devido ao risco de neurite &#xF3;ptica por etambutol. No segundo m&#xEA;s de
tratamento, foi evidenciado borramento bilateral do disco &#xF3;ptico. Nessa mesma &#xE9;poca,
o resultado da baciloscopia e da cultura da bi&#xF3;psia de linfonodo mostraram-se
positivos para o complexo <italic>M. tuberculosis</italic>, com teste de
sensibilidade demonstrando resist&#xEA;ncia &#xE0; isoniazida. Tendo em vista a melhora parcial
da linfadenite e a possibilidade de neurite &#xF3;ptica medicamentosa, o etambutol foi
suspenso, sendo mantidos rifampicina e isoniazida apesar da resist&#xEA;ncia a
isoniazida.</p>
        <p>No oitavo m&#xEA;s de tratamento, a lactente foi internada com infec&#xE7;&#xE3;o secund&#xE1;ria no
s&#xED;tio da bi&#xF3;psia. A TC de t&#xF3;rax realizada durante a interna&#xE7;&#xE3;o mostrou
linfadenomegalia axilar direita difusa e coalescente, com linfonodos necr&#xF3;ticos e
fistulizantes, o que indicava les&#xE3;o em atividade. Uma nova bi&#xF3;psia linfonodal foi
realizada e encaminhada para a an&#xE1;lise micobacteriol&#xF3;gica e molecular da cepa ao
Centro de Refer&#xEA;ncia Professor H&#xE9;lio Fraga, localizado na cidade do Rio de Janeiro.
Os exames laboratoriais revelaram que se tratava da cepa do <italic>M. bovis</italic>
BCG. Os testes de identifica&#xE7;&#xE3;o realizados foram testes bioqu&#xED;micos b&#xE1;sicos e o
m&#xE9;todo molecular <italic>polymerase chain reaction restriction analysis </italic>do
gene<italic> hsp65</italic>. O teste de sensibilidade foi realizado em meio
l&#xED;quido automatizado BACTEC <italic>Mycobacteria Growth Indicator Tube</italic>
(MGIT) 960 (Becton Dickinson, Sparks, MD, EUA), o qual revelou resist&#xEA;ncia a
isoniazida e tamb&#xE9;m a rifampicina. Foi realizado o sequenciamento dos genes
<italic>rpo</italic>B, com detec&#xE7;&#xE3;o de muta&#xE7;&#xE3;o em D516V, e <italic>kat</italic>G,
com muta&#xE7;&#xE3;o em S315T.</p>
        <p>Diante dos resultados, optou-se pela manuten&#xE7;&#xE3;o do tratamento com isoniazida, retorno
do uso de etambutol e acompanhamento oftalmol&#xF3;gico semanal, al&#xE9;m da associa&#xE7;&#xE3;o de 30
doses de estreptomicina (25 mg/kg ao dia) em dias alternados por seis meses e
suspens&#xE3;o do uso de rifampicina. A les&#xE3;o oftalmol&#xF3;gica manteve-se est&#xE1;vel durante
todo o tratamento. Diante da dificuldade do caso, a estreptomicina foi indicada por
ser bactericida e de primeira linha, assim pela falta de conhecimento da real
resposta da isoniazida in vivo<italic>.</italic>
</p>
        <p>A hip&#xF3;tese de defeito no eixo IFN-&#x3B3;/IL-12 foi confirmada por testes moleculares que
identificaram muta&#xE7;&#xE3;o em homozigose no receptor &#x3B2;<sub>1</sub> de IL-12, excluindo uma
prov&#xE1;vel imunodefici&#xEA;ncia combinada grave (IDCG). Dessa forma, IFN-&#x3B3; subcut&#xE2;neo foi
associado ao tratamento tr&#xEA;s vezes na semana.</p>
        <p>Ap&#xF3;s seis meses de tratamento, a les&#xE3;o axilar havia regredido completamente (<xref ref-type="fig" rid="f04">Figura 2</xref>). At&#xE9; o momento, tr&#xEA;s anos ap&#xF3;s o in&#xED;cio
do quadro, a paciente mantinha-se sem a linfadenite, e a les&#xE3;o ocular permanecia
est&#xE1;vel, sem repercuss&#xF5;es visuais.</p>
        <p>
<fig id="f04" orientation="portrait" position="float"><label>Figura 2</label><caption><title>Les&#xE3;o cicatrizada na regi&#xE3;o axilar e infra-axilar direita ap&#xF3;s o
tratamento.</title></caption><graphic xlink:href="1806-3713-jbpneu-40-02-00188-gf02-pt"/></fig>
</p>
      </sec>
      <sec>
        <title>Discuss&#xE3;o</title>
        <p>As rea&#xE7;&#xF5;es adversas &#xE0; vacina BCG variam com o tipo da cepa, carga bacilar,
administra&#xE7;&#xE3;o da vacina e caracter&#xED;sticas do hospedeiro. A linfadenite n&#xE3;o supurativa
reacional pode ocorrer em crian&#xE7;as nos primeiros meses ap&#xF3;s a aplica&#xE7;&#xE3;o da vacina e
decorre, em sua maioria, da t&#xE9;cnica incorreta na aplica&#xE7;&#xE3;o. A isoniazida vem sendo
empregada no Brasil para o tratamento da linfadenopatia supurada secund&#xE1;ria &#xE0; vacina
em pacientes imunocompetentes. Essa recomenda&#xE7;&#xE3;o baseia-se no fato de que a cepa
brasileira da vacina BCG normalmente &#xE9; sens&#xED;vel a essa droga em testes in
vitro.<sup>(</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> Por&#xE9;m, no presente caso, foi demonstrada a resist&#xEA;ncia do bacilo BCG a
isoniazida e rifampicina, com prov&#xE1;vel resposta in vivo quando associadas a outros
f&#xE1;rmacos.</p>
        <p>No entanto, a vacina pode causar complica&#xE7;&#xF5;es mais graves e que, na maioria das
vezes, ocorrem em pacientes com imunodepress&#xE3;o. Estima-se que a incid&#xEA;ncia de doen&#xE7;a
disseminada pelo <italic>M. bovis</italic> BCG em pa&#xED;ses da Europa seja de dois casos
para cada 1.000.000 de crian&#xE7;as vacinadas, ocorrendo apenas ocasionalmente em
crian&#xE7;as imunocompetentes.<sup>(</sup>
<xref rid="B08" ref-type="bibr">
<sup>8</sup>
</xref>
<sup>)</sup> Talbot et al. descreveram em seu estudo uma taxa de 86% de defeitos
imunol&#xF3;gicos em crian&#xE7;as com diagn&#xF3;stico da doen&#xE7;a disseminada.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>)</sup> Existem casos relatados na literatura de complica&#xE7;&#xF5;es em pacientes
infectados pelo HIV e em pacientes com imunodefici&#xEA;ncia prim&#xE1;ria.<sup>(</sup>
<xref rid="B04" ref-type="bibr">
<sup>4</sup>
</xref>
<sup>,</sup>
<xref rid="B07" ref-type="bibr">
<sup>7</sup>
</xref>
<sup>)</sup> Hesseling et al. descreveram uma s&#xE9;rie de 25 pacientes diagnosticados
com infec&#xE7;&#xE3;o grave por <italic>M. bovis</italic> vacinal associada &#xE0; imunodefici&#xEA;ncia
prim&#xE1;ria.<sup>(</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> Santos et al. descreveram tr&#xEA;s casos de pacientes com a infec&#xE7;&#xE3;o
vacinal, sendo um deles com defici&#xEA;ncia no eixo IFN-&#x3B3;/IL-12.<sup>(</sup>
<xref rid="B03" ref-type="bibr">
<sup>3</sup>
</xref>
<sup>)</sup> O defeito no eixo IFN-&#x3B3;/IL-12 &#xE9; uma imunodefici&#xEA;ncia na qual h&#xE1; uma
susceptibilidade aumentada a infec&#xE7;&#xF5;es por microrganismos dos g&#xEA;neros
<italic>Mycobacterium</italic> e <italic>Salmonella</italic>.<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>,</sup>
<xref rid="B12" ref-type="bibr">
<sup>12</sup>
</xref>
<sup>)</sup> &#xC9; classificada como um defeito cong&#xEA;nito de fag&#xF3;citos em n&#xFA;mero, fun&#xE7;&#xE3;o
ou ambos. As defesas do hospedeiro para essas bact&#xE9;rias dependem fortemente da
integridade funcional dos fag&#xF3;citos mononucleares e sua intera&#xE7;&#xE3;o com os linf&#xF3;citos
T. Linf&#xF3;citos T e c&#xE9;lulas <italic>natural killer</italic> de pacientes afetados
expressam um receptor de IL-12 defeituoso em suas superf&#xED;cies celulares, levando a
uma baixa produ&#xE7;&#xE3;o de IFN-&#x3B3;, sendo esse o principal fator respons&#xE1;vel pela morte da
micobact&#xE9;ria.<sup>(</sup>
<xref rid="B13" ref-type="bibr">
<sup>13</sup>
</xref>
<sup>)</sup> O diagn&#xF3;stico dos defeitos no eixo IFN-&#x3B3;/IL-12 requer uma abordagem
escalonada e com apoio laboratorial.<sup>(</sup>
<xref rid="B14" ref-type="bibr">
<sup>14</sup>
</xref>
<sup>)</sup> Em pacientes com infec&#xE7;&#xE3;o micobacteriana disseminada e grave, deve-se
primeiramente excluir outras imunodefici&#xEA;ncias, como a imunodefici&#xEA;ncia combinada
grave. Em alguns casos, o tratamento de defeitos no eixo IFN-&#x3B3;/IL-12 exige o uso
agressivo de f&#xE1;rmacos contra a micobact&#xE9;ria e a reposi&#xE7;&#xE3;o com IFN-&#x3B3; subcut&#xE2;neo como
uma op&#xE7;&#xE3;o terap&#xEA;utica.<sup>(</sup>
<xref rid="B11" ref-type="bibr">
<sup>11</sup>
</xref>
<sup>)</sup> No relato do presente caso, demonstramos por exames complementares essa
defici&#xEA;ncia, o que favoreceu o desenvolvimento da les&#xE3;o pelo <italic>M.
bovis</italic> BCG.</p>
        <p>Um sistema de classifica&#xE7;&#xE3;o da doen&#xE7;a causada pelo <italic>M. bovis</italic> vacinal
em pacientes imunossuprimidos foi desenvolvido por Talbot et al. e posteriormente
revisado por Hesseling et al.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup> A infec&#xE7;&#xE3;o &#xE9; classificada de acordo com sua apresenta&#xE7;&#xE3;o em doen&#xE7;a
local, regional, distante e disseminada. A doen&#xE7;a regional &#xE9; descrita como aquela com
les&#xE3;o no local de inocula&#xE7;&#xE3;o da vacina e envolvimento de linfonodo regional
ipsilateral, com linfadenomegalia, supura&#xE7;&#xE3;o e/ou forma&#xE7;&#xE3;o de f&#xED;stulas, conforme
observado no caso descrito.<sup>(</sup>
<xref rid="B09" ref-type="bibr">
<sup>9</sup>
</xref>
<sup>,</sup>
<xref rid="B10" ref-type="bibr">
<sup>10</sup>
</xref>
<sup>)</sup>
</p>
        <p>Relatamos a evolu&#xE7;&#xE3;o da infec&#xE7;&#xE3;o pelo <italic>M. bovis</italic> vacinal em uma
lactente com imunodefici&#xEA;ncia prim&#xE1;ria que apresentou les&#xE3;o regional ipsilateral &#xE0;
vacina, n&#xE3;o responsiva ao tratamento preconizado com isoniazida, sendo a cepa
resistente a dois f&#xE1;rmacos (rifampicina e isoniazida). Apesar de o resultado do teste
de sensibilidade ter demonstrado resist&#xEA;ncia a isoniazida, optou-se pela manuten&#xE7;&#xE3;o
dessa medica&#xE7;&#xE3;o j&#xE1; que testes utilizando uma concentra&#xE7;&#xE3;o cr&#xED;tica n&#xE3;o revelam a
realidade quantitativa da resist&#xEA;ncia (baixa, moderada ou alta), a qual &#xE9; determinada
por <italic>minimum inhibitory concentration</italic> (MIC, concentra&#xE7;&#xE3;o inibit&#xF3;ria
m&#xED;nima).<sup>(</sup>
<xref rid="B15" ref-type="bibr">
<sup>15</sup>
</xref>
<sup>)</sup> N&#xE3;o h&#xE1; como afirmar a rela&#xE7;&#xE3;o quantitativa in vitro da resist&#xEA;ncia a
isoniazida j&#xE1; que a MIC n&#xE3;o foi realizada, e a muta&#xE7;&#xE3;o encontrada pode estar
relacionada &#xE0; resist&#xEA;ncia moderada a isoniazida (<italic>kat</italic>G, muta&#xE7;&#xE3;o
S315T), al&#xE9;m de n&#xE3;o refletir a realidade in vivo. Com a retirada do etambutol devido
a suspeita de neurite &#xF3;ptica, pode ter havido uma sele&#xE7;&#xE3;o das cepas, com aquisi&#xE7;&#xE3;o da
resist&#xEA;ncia a rifampicina. A rifampicina n&#xE3;o foi mantida, pois a muta&#xE7;&#xE3;o encontrada
na regi&#xE3;o <italic>rpo</italic>B (muta&#xE7;&#xE3;o D516V) est&#xE1; na grande maioria das vezes
relacionada a um alto n&#xED;vel de resist&#xEA;ncia.<sup>(15) </sup>Estudos de muta&#xE7;&#xF5;es e de
MIC associados &#xE0; resposta cl&#xED;nica foram descritos para o <italic>M.
tuberculosis</italic>, mas n&#xE3;o h&#xE1; relatos na literatura referentes ao <italic>M.
bovis</italic> BCG.</p>
        <p>Foi descartada a neurite &#xF3;ptica pela a&#xE7;&#xE3;o de etambutol, j&#xE1; que a altera&#xE7;&#xE3;o do disco
&#xF3;ptico manteve-se est&#xE1;vel durante todo o acompanhamento da lactente. O desfecho
favor&#xE1;vel, apesar da resist&#xEA;ncia a isoniazida, foi poss&#xED;vel pela associa&#xE7;&#xE3;o de
estreptomicina e etambutol, assim como pela inclus&#xE3;o do imunomodulador, o que
possibilitou a cura das les&#xF5;es.</p>
      </sec>
    </body>
    <back>
      <fn-group>
        <fn id="fn02" fn-type="other">
          <label>*</label>
          <p>Trabalho realizado na Universidade Federal de Minas Gerais, Belo Horizonte (MG)
Brasil.</p>
        </fn>
        <fn fn-type="supported-by">
          <p>Apoio financeiro: Este estudo recebeu apoio financeiro da Funda&#xE7;&#xE3;o de Amparo &#xE0;
Pesquisa do Estado de Minas Gerais (FAPEMIG).</p>
        </fn>
      </fn-group>
    </back>
  </sub-article>
</article>
</pmc-articleset>
